» Articles » PMID: 9700924

Deciphering the Fluorescence Signature of Daunomycin and Doxorubicin

Overview
Journal Biophys Chem
Specialty Biochemistry
Date 1998 Aug 13
PMID 9700924
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

The fluorescence characteristics of daunomycin (DNM), doxorubicin (DXR), and other anthracycline drugs are often used to monitor localization of the drug within lipid bilayers and liposomal delivery systems and to assess interaction of the drug with DNA and other macromolecules. However, the binding of DNM and DXR to proteins and membrane systems has been observed to exhibit variable effects on the anthracycline's fluorescence. We have delineated the spectroscopic response of DXR and DNM to their surroundings in several systems, including solvents of differing dielectric constant, aqueous solutions of varying pH or fluorophore concentration, and the reverse micellar system of AOT/heptane/water with a range of doxorubicin concentrations. We have observed that the ratio of fluorescence intestinal at the two principal lambda max values shows a parabolic dependence on solvent dielectric constant, i.e. inverted solvatochromism. This behavior has been overlooked by previous investigators and, together with the appearance of a long-wavelength band near 630 nm in solvents of low dielectric strength (also previously not reported), is key to understanding the partitioning of anthracyclines in membrane systems as well as resolving the conflicting interpretation of data in the literature.

Citing Articles

Synergistic anti-cancer effects of piezoelectric hexagonal boron nitride nanocarriers for controlled doxorubicin release.

Cicek N, Cobandede Z, Adiguzel S, Yilmaz H, Culha M Nanomedicine (Lond). 2025; 20(5):455-466.

PMID: 39887263 PMC: 11875468. DOI: 10.1080/17435889.2025.2459055.


Physicochemical characterization and potential cancer therapy applications of hydrogel beads loaded with doxorubicin and GaOOH nanoparticles.

Zmuda A, Kaminska W, Bartel M, Glowacka K, Chotkowski M, Medynska K Sci Rep. 2024; 14(1):20822.

PMID: 39242631 PMC: 11379898. DOI: 10.1038/s41598-024-67709-z.


Biogenic nanoparticles: pioneering a new era in breast cancer therapeutics-a comprehensive review.

Bhat S, Kumar V, Dhanjal D, Gandhi Y, Mishra S, Singh S Discov Nano. 2024; 19(1):121.

PMID: 39096427 PMC: 11297894. DOI: 10.1186/s11671-024-04072-y.


A PSMA-targeted doxorubicin small-molecule drug conjugate.

Yoon H, Savoy E, Mesbahi N, Hendricksen A, March G, Fulton M Bioorg Med Chem Lett. 2024; 104:129712.

PMID: 38521177 PMC: 11062396. DOI: 10.1016/j.bmcl.2024.129712.


Quantitative imaging of doxorubicin diffusion and cellular uptake in biomimetic gels with human liver tumor cells.

Degerstedt O, OCallaghan P, Lerma Clavero A, Grasjo J, Eriksson O, Sjogren E Drug Deliv Transl Res. 2023; 14(4):970-983.

PMID: 37824040 PMC: 10927899. DOI: 10.1007/s13346-023-01445-1.